Singapore whistling as Penthrox arrives
Medical device manufacturer Medical Developments International (ASX:MVP) has received regulatory approval from the Health Sciences Authority in Singapore to market and sell Penthrox. MVP is the only global supplier of Penthrox, an emergency pain relief device developed in Australia and commonly known as “the green whistle”. The approval follows the recent European licence, development and commercialisation agreement that was finalised between MVP and Mundipharma International, with Mundipharma paying MVP upfront and milestone payments of up to $54.5 million US dollars. MVP shares have risen significantly in September, and closed up 9.8% for the week. We own MVP in the investment portfolio.
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.

1 topic
1 stock mentioned
Please sign in to comment on this wire.